Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
Using artificial intelligence (AI) to analyze electrocardiograms (ECG) improved detection of severe heart attacks, including those that presented with unconventional symptoms, or atypical ECG patterns ...
TORONTO, ON / ACCESS Newswire / November 24, 2025 / NeuralCloud Solutions Inc. ("Neural Cloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is ...
TORONTO, ON / ACCESS Newswire / March 25, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is ...
Patent validates AIML's novel neural-network approach to denoising and mapping ECG signals, powering MaxYield™ and CardioYield™. Reinforces competitive advantage as the Company advances ...
Burnout and chronic fatigue carry a substantial economic cost and pose serious risks in professions where alertness is ...
Collaboration Expands Reach of MaxYield into Remote Heart Monitoring and Preventive Cardiology Applications TORONTO, ON / ACCESS Newswire / March 31, 2026 / AI/ML Innovations Inc. ("AIML" or the "Comp ...
TORONTO, ON / ACCESS Newswire / February 12, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is ...
Atrial fibrillation (AF) represents a complex disorder of cardiac rhythm, deeply rooted in the intricate interplay between molecular, cellular, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results